Telotristat Ethyl (Xermelo™): First Global Approval – first and only oral drug for cancer-related diarrhoea syndrome

Telotristat Ethyl (Xermelo™): First Global Approval – first and only oral drug for cancer-related diarrhoea syndrome

The recent first global approval of telotristat ethyl has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

Continue reading “Telotristat Ethyl (Xermelo™): First Global Approval – first and only oral drug for cancer-related diarrhoea syndrome”

AdisInsight is PRIMEd

AdisInsight is PRIMEd

Adis adds PRIME status to AdisInsight drug profiles.

In 2016, the European Medicines Agency launched PRIME – a program to enhance support for the development of medicines that target an unmet medical need. This voluntary program is based on enhanced interaction and early dialogue with developers of promising medicine, to optimise development plans and speed up evaluation so that these medicines can reach patients earlier.

Continue reading “AdisInsight is PRIMEd”

Personalized Frequently Searched Terms added to AdisInsight

Personalized Frequently Searched Terms added to AdisInsight

Searching AdisInsight has become even more intuitive with the implementation of personalized frequently searched terms.  Your 10 most frequently searched terms will now be displayed in bold font on the advanced search page.  This will make the terms you search most often stand out from all the available terms while still allowing those other terms to be displayed in case you need them in the future. Continue reading “Personalized Frequently Searched Terms added to AdisInsight”